


Almorexant

Cat. No.:	HY-10805		
CAS No.:	871224-64-5		
Molecular Formula:	C ₂₉ H ₃₁ F ₃ N ₂ O ₃		
Molecular Weight:	512.56		
Target:	Orexin Receptor (OX Receptor)		
Pathway:	GPCR/G Protein; Neuronal Signaling		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 46 mg/mL (89.75 mM)
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	1.9510 mL	9.7550 mL	19.5099 mL
	5 mM	0.3902 mL	1.9510 mL	3.9020 mL
	10 mM	0.1951 mL	0.9755 mL	1.9510 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 2.5 mg/mL (4.88 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
 Solubility: ≥ 2.5 mg/mL (4.88 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: ≥ 2.5 mg/mL (4.88 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Almorexant (ACT 078573) is a potent and competitive dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist with K_i values of 1.3 and 0.17 nM, respectively.

IC₅₀ & Target

IC₅₀: 1.3/0.7 nM(OX1/OX2 Receptor)

- Cell Metab. 2018 Jul 3;28(1):118-129.e5.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Cruz HG, et al. Assessment of the abuse liability of a dual orexin receptor antagonist: a crossover study of almorexant and zolpidem in recreational drug users. *CNS Drugs*. 2014 Apr;28(4):361-72.
- [2]. Malherbe P, et al. Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison with selective OX1 and OX2 antagonists. *Mol Pharmacol*. 2009 Sep;76(3):618-31.
- [3]. Sifferlen T, et al. Novel pyrazolo-tetrahydropyridines as potent orexin receptor antagonists. *Bioorg Med Chem Lett*. 2010 Mar 1;20(5):1539-42.
- [4]. Black SW, et al. Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsy. *Sleep*. 2013 Mar 1;36(3):325-36.
- [5]. Dayot S, et al. In vitro, in vivo and ex vivo demonstration of the antitumoral role of hypocretin-1/orexin-A and almorexant in pancreatic ductal adenocarcinoma. *Oncotarget*. 2018 Jan 9;9(6):6952-6967.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA